Silvercrest Asset Management’s Home BancShares HOMB Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2024
Q4
Sell
-610,373
Closed -$16.5M 847
2024
Q3
$16.5M Buy
610,373
+105,213
+21% +$2.8M 0.11% 198
2024
Q2
$12.1M Buy
505,160
+95,550
+23% +$2.27M 0.08% 237
2024
Q1
$10.1M Buy
409,610
+1,821
+0.4% +$43.3K 0.07% 262
2023
Q4
$10.3M Sell
407,789
-48,336
-11% -$1.08M 0.07% 241
2023
Q3
$9.55M Buy
456,125
+11,659
+3% +$265K 0.07% 240
2023
Q2
$10.1M Buy
444,466
+21,605
+5% +$471K 0.07% 234
2023
Q1
$9.18M Sell
422,861
-7,037
-2% -$162K 0.07% 241
2022
Q4
$9.8M Sell
429,898
-35,135
-8% -$852K 0.08% 223
2022
Q3
$10.5M Sell
465,033
-32,787
-7% -$761K 0.09% 216
2022
Q2
$10.3M Sell
497,820
-7,542
-1% -$163K 0.08% 229
2022
Q1
$11.4M Sell
505,362
-6,298
-1% -$149K 0.07% 237
2021
Q4
$12.5M Buy
+511,660
New +$12.6M 0.08% 236
2020
Q1
Sell
-592,971
Closed -$11.7M 744
2019
Q4
$11.7M Sell
592,971
-3,871
-0.6% -$73K 0.09% 218
2019
Q3
$11.2M Buy
+596,842
New +$11.2M 0.09% 211

Other funds holding HOMB

Silvercrest Asset Management's HOMB Position: Q4 2024 in Review

Silvercrest Asset Management sold out of Home BancShares (HOMB) in Q4 2024, closing a stake of 610,373 shares — an estimated $16.5M sold.

Silvercrest Asset Management first reported a position in HOMB in Q3 2019 and held it in 14 quarters. The position peaked at $16.5M in Q3 2024. 328 funds tracked by Wall St. Rank hold HOMB as of Q4 2024.

  • Silvercrest Asset Management reported no remaining Home BancShares position as of Q4 2024 after selling out during the quarter.
  • Silvercrest Asset Management sold 610,373 Home BancShares shares in Q4 2024, an estimated $16.5M.
  • Silvercrest Asset Management first reported a position in Home BancShares in Q3 2019 and held it in 14 quarters.
  • Silvercrest Asset Management's Home BancShares position peaked at $16.5M in Q3 2024.
  • 328 funds tracked by Wall St. Rank held Home BancShares as of Q4 2024.

Based on Silvercrest Asset Management's 13F filing for Q4 2024, filed 14 Feb 2025.